Skip to main content

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Nephrology
8
Pipeline Programs
4
Companies
9
Clinical Trials
2 recruiting
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
2
4
Early DiscoveryClinical DevelopmentMarket

Nephrology is a $36.6B mature market dominated by cardiometabolic crossover drugs with limited pure renal innovation.

$36.6B marketMature→ Stable30 products15 companies

Key Trends

  • GLP-1 agonists and SGLT2 inhibitors dominate (69% of spending) due to dual cardio-renal benefits
  • Patent cliffs approaching 2026-2030 create generic conversion risk for blockbuster franchises
  • Pipeline activity remains robust (2,785 trials) but concentrated in early-phase basic research

Career Verdict

Nephrology offers stable employment in commercial and medical affairs roles, but limited growth upside due to mature blockbuster dependency and declining pure renal research focus.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1OZEMPICStable
$9.2B
Novo Nordisk·Peak12.4yr
#2JARDIANCEStable
$8.8B
#4FARXIGAStable
$4.3B
AstraZeneca·Peak15.4yr

Drug Class Breakdown

Glucagon-like Peptide-1 (GLP-1) Agonists
$16.6B(45%)

cardiometabolic dominance

Sodium-Glucose Transporter 2 Inhibitors
$8.8B(24%)

cardioprotective expansion

SGLT2 Inhibitors (dapagliflozin class)
$4.3B(12%)

heart failure crossover

Adrenergic Beta3-Agonists
$3.0B(8%)

overactive bladder niche

Dipeptidyl Peptidase 4 Inhibitors
$1.3B(4%)

declining relevance

Career Outlook

Stable

Nephrology careers are stable but not expanding; the field is supported by blockbuster drugs (GLP-1s, SGLT2i) that face patent cliffs between 2026–2041, creating near-term employment security but long-term uncertainty. Commercial and medical affairs roles dominate hiring, while R&D investment is limited to niche mechanisms (complement inhibition, gene therapy). Career progression depends on specialization in medtech, diagnostics, or orphan nephrology rather than traditional pharma blockbuster development.

Breaking In

Target medtech platforms (Outset, Fresenius) or biotech innovators (Vertex, Calyxo) over traditional pharma; nephrology offers job stability and clinical depth but limited growth trajectory in pure pharmaceutical roles.

For Experienced Professionals

Leverage cardiometabolic expertise to span diabetes, CKD, and HF franchises; position for transition to orphan nephrology (ADPKD, FSGS, IgA) where innovation and valuation multiples are highest.

In-Demand Skills

Renal endpoints and biomarkers (eGFR, albuminuria)Cardio-renal crossover knowledge (diabetes + CKD + HF)Medtech systems expertise (dialysis, transplantation platforms)Medical affairs and key opinion leader management

Best For

Medical Science Liaison (renal specialists)Commercial Manager (established nephro franchise)Clinical Development Manager (rare kidney disease)Real-world evidence analyst (CKD outcomes)

Hiring Landscape

$108K–$330K

Nephrology hiring is concentrated in commercial roles (58 positions, $108K avg) and medical affairs (12 positions, $330K avg), reflecting mature market dynamics. Top hiring companies are innovative platforms (Vertex: 41 jobs) and medtech (Outset: 21 jobs), not traditional pharma. Salary compression in commercial roles suggests commoditization.

124
Open Roles
5
Companies Hiring
4
Departments

Top Hiring Companies

20Growing
8Stable

By Department

Commercial(47%)
$108K
Medical Affairs(10%)
$330K
Clinical Excellence(6%)
$140K
Quality Assurance(4%)
$201K

Hiring favors medtech and biotech platforms over traditional pharma; medical affairs offers premium compensation but limited volume; commercial roles are abundant but underpaid relative to other therapeutic areas.

On Market (3)

Approved therapies currently available

Otsuka
JYNARQUEApproved
tolvaptan
Otsuka
Vasopressin V2 Receptor Antagonist [EPC]oral2018
76M Part D
Otsuka
SAMSCAApproved
tolvaptan
Otsuka
Vasopressin V2 Receptor Antagonist [EPC]oral2009
12M Part D
Otsuka
TOLVAPTANApproved
tolvaptan
Otsuka
oral2025
3M Part D

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Otsuka
OtsukaJapan - Tokushima
3 programs
2
1
TolvaptanPhase 41 trial
TolvaptanPhase 31 trial
TolvaptanPhase 31 trial
Active Trials
NCT02964273Completed91Est. Nov 2021
NCT01214421Completed1,083Est. Feb 2016
NCT03949894Completed118Est. May 2022
Rege Nephro
Rege NephroJapan - Kyoto
1 program
1
TamibarotenePhase 21 trial
Active Trials
NCT06289998Active Not Recruiting70Est. Dec 2025
PYC Therapeutics
PYC TherapeuticsAustralia - Nedlands
1 program
1
PYC-003Phase 11 trial
Active Trials
NCT06714006Recruiting116Est. Mar 2027
Vertex Pharmaceuticals
4 programs
VX-407PHASE_11 trial
VX-407PHASE_11 trial
VX-407PHASE_11 trial
VX-407PHASE_21 trial
Active Trials
NCT07074327Completed74Est. Feb 2026
NCT06345755Completed159Est. Jun 2025
NCT07022119Completed32Est. Feb 2026
+1 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
OtsukaTolvaptan
OtsukaTolvaptan
OtsukaTolvaptan
Vertex PharmaceuticalsVX-407
Rege NephroTamibarotene
Vertex PharmaceuticalsVX-407
Vertex PharmaceuticalsVX-407
PYC TherapeuticsPYC-003
Vertex PharmaceuticalsVX-407

Clinical Trials (9)

Total enrollment: 1,767 patients across 9 trials

Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease

Start: Jul 2019Est. completion: May 2022118 patients
Phase 4Completed

Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)

Start: Sep 2016Est. completion: Nov 202191 patients
Phase 3Completed

Tolvaptan Extension Study in Participants With ADPKD

Start: May 2010Est. completion: Feb 20161,083 patients
Phase 3Completed

Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

Start: Nov 2025Est. completion: Dec 202724 patients
Phase 2Recruiting

Study of Tamibarotene in Patients With ADPKD

Start: Dec 2023Est. completion: Dec 202570 patients
Phase 2Active Not Recruiting

Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants

Start: Jul 2025Est. completion: Feb 202674 patients
Phase 1Completed

A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants

Start: Jun 2025Est. completion: Feb 202632 patients
Phase 1Completed

Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003

Start: Apr 2025Est. completion: Mar 2027116 patients
Phase 1Recruiting

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants

Start: Apr 2024Est. completion: Jun 2025159 patients
Phase 1Completed

Related Jobs in Nephrology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
2 actively recruiting trials targeting 1,767 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.